AbCellera Biologics Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
AbCellera Biologics Inc. (ABCL) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of -$468.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$38.00K, a 106.44% decline year-over-year.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $590.00K.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$781.00K.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$213.00K.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $1.10M.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$2.62M, a 544.31% decline from fiscal 2023.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $589.00K.
- AbCellera Biologics Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$9.60M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$468.00K 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | -$38.00K 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $1.10M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $807.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.35M 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $590.00K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$2.62M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -$457.00K 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$824.00K 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$781.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $589.00K 10-K · filed 2026-02-24 | |||
| 2023-09-30 | -$479.00K 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | $584.00K 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$213.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$9.60M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$9.96M 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | -$1.41M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | -$204.00K 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | -$1.43M 10-K · filed 2024-02-20 | |||
| 2021-09-30 | -$900.00K 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | -$683.00K 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | -$484.00K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |